News > RMMS Defeats Motion for Preliminary Injunction Involving Generic Carbamazepine Extended-Release Capsules
RMMS Defeats Motion for Preliminary Injunction Involving Generic Carbamazepine Extended-Release Capsules
On July 6, 2011, the U.S. District Court for the District of New Jersey denied a motion for a preliminary injunction that would have blocked full generic competition for carbamazepine extended-release capsules. Nostrum Pharmaceuticals sought a preliminary injunction prohibiting FDA from approving otherwise eligible abbreviated new drug applications (ANDAs) for carbamazepine extended-release capsules even after patent expiration. The denial permits the FDA to approve eligible ANDAs for carbamazepine extended-release capsules as Nostrum continues its case against FDA. Lara FitzSimmons, who argued for the firm's client, William Rakoczy, Christine Siwik, and Eric Hunt handled the case for the firm's client.